Tempest Therapeutics, Inc.
TPST
$0.91
-$0.08-7.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -36.76% | 53.34% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.22% | 35.86% | |||
| Operating Income | 5.22% | -35.86% | |||
| Income Before Tax | 81.07% | -588.78% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 81.07% | -588.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 81.07% | -588.78% | |||
| EBIT | 5.22% | -35.86% | |||
| EBITDA | 5.27% | -36.57% | |||
| EPS Basic | 86.40% | -209.20% | |||
| Normalized Basic EPS | 31.74% | 38.41% | |||
| EPS Diluted | 86.40% | -209.20% | |||
| Normalized Diluted EPS | 31.74% | 38.41% | |||
| Average Basic Shares Outstanding | 39.27% | 122.77% | |||
| Average Diluted Shares Outstanding | 39.27% | 122.77% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||